Novo Nordisk’s Data Breach and Clinical Defeat Leave Investors with Little to Cheer

The Danish drugmaker entered the week with a promising oral medication and emerged facing a cybersecurity crisis and a clinical defeat at the hands of its biggest rival. Novo Nordisk now has to contend with both a stolen cache of patient data and a pill that has lost its scientific edge.

Hacker Attack Exposes Patient Information

On Thursday, the company disclosed an unauthorized intrusion into its internal IT systems. External cybersecurity specialists are now investigating the breach. As a precaution, Novo took certain networks offline, though it stressed that core operations are running normally.

The attackers made off with sensitive material, including personal data belonging to participants in clinical trials. Novo is currently notifying affected individuals and cooperating with authorities. The full scope of the data theft and any potential regulatory penalties now define a new short-term risk for the stock.

Lilly’s Pill Triumphs in Head-to-Head Trial

The cyber incident came just days after Eli Lilly dealt a severe blow to Novo’s ambitions in oral GLP-1 therapies. The FDA approved Lilly’s obesity pill orforglipron, branded as Foundayo, which was immediately rolled out via LillyDirect at $25 a month with insurance coverage or $149 for self-paying patients.

The real damage, however, came from the ACHIEVE-3 study. Orforglipron outperformed Novo’s oral semaglutide directly: patients with type 2 diabetes achieved a 2.2% reduction in blood sugar versus 1.4% for Novo’s drug, while weight loss reached 9.2% compared with 5.3%. These numbers are difficult to dispute.

Adding to the competitive pressure, Lilly’s pill targets both obesity and diabetes, whereas oral Wegovy is approved solely for weight loss. In a separate head-to-head trial against Novo’s diabetes pill Rybelsus, orforglipron also emerged victorious. Novo cannot quickly match this dual advantage.

CagriSema Holds Promise but Faces Long Wait

Before the hack made headlines, Novo had presented encouraging results for its own pipeline candidate, CagriSema. At the American Diabetes Association congress, data from the REIMAGINE studies showed that the combination of semaglutide and cagrilintide significantly lowered long-term blood sugar and body weight in adults with type 2 diabetes, meeting all primary endpoints.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The FDA is expected to decide on CagriSema’s approval for weight reduction in the fourth quarter of 2026. Until then, Novo remains exposed to Lilly’s increasingly dominant pipeline. Retatrutide, Lilly’s triple agonist, delivered a mean weight loss of 28.7% over 68 weeks in a phase-3 trial – a figure that dwarfs any rival’s performance so far.

Stock Buyback Fails to Inspire

Amid these crosscurrents, Novo has continued its massive share repurchase program. Between June 1 and 4, it bought back 870,000 B-shares, bringing total buybacks in 2026 to 18.76 million B-shares. The current program runs up to DKK 11.2 billion as part of a total DKK 15 billion authorization.

Yet the stock closed Friday at €38.03, down nearly 15% year-to-date and roughly 46% below its 52-week high of €70.13. The buyback demonstrates financial discipline but does nothing to close the competitive gap with Lilly. The relative strength index of 53.6 and a 26% recovery from the 52-week low of €30.25 suggest the market is pricing in stabilisation, not a turnaround. Shares currently sit just above their 50-day moving average of €36.38.

Medicare Boost Ahead, but Patent Cliffs Loom

A near-term catalyst arrives on July 1, when Medicare Part D coverage for Wegovy takes effect in the US, which could expand the patient pool meaningfully. However, patent protection for semaglutide expires in several key markets in 2026 – Canada, Brazil and China – just as Novo most needs volume growth.

The broader overhang remains Novo’s own guidance from February, which projected a 5–13% revenue decline at constant exchange rates for 2026, far below analyst expectations at the time. Until a quarterly report convincingly breaks that trajectory, the outlook will continue to weigh on the share price.

Analysts Cautious on Near-Term Outlook

With the extent of the data breach still unclear and the FDA decision on CagriSema months away, the stock is vulnerable to operational shocks. The consensus of 23 analysts stands at “Neutral,” with an average price target of roughly DKK 312. For now, Novo remains a structurally sound company trapped in a structurally difficult moment – fighting a pill war it is losing clinically while cleaning up a digital mess that has undercut investor confidence.